Stocks · News reference
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $210.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.
Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from analysts. Uber and Amcor shares fell, while Tanger, Rockwell Automation, and Neurocrine Biosciences shares all had varying degrees of movement.